Insys Therapeutics Inc (INSY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Insys Therapeutics Inc (INSY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9766
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship product, Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP). Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
INSYS Therapeutics Expands Agreement with University of California San Diego 12
Licensing Agreements 13
INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13
Insys Therapeutics Enters into Licensing Agreement with Senzer 14
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16
Equity Offering 17
Insys Therapeutics Completes IPO For US$36.8 Million 17
Insys Therapeutics Inc – Key Competitors 19
Insys Therapeutics Inc – Key Employees 20
Insys Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Nov 05, 2018: INSYS Therapeutics reports third quarter 2018 results 22
Aug 08, 2018: INSYS Therapeutics reports second quarter 2018 results 25
May 08, 2018: INSYS Therapeutics Reports First Quarter 2018 Results 27
Mar 08, 2018: INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results 29
Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 30
Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 31
May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 32
Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 33
Corporate Communications 35
Oct 10, 2018: INSYS Therapeutics names new general counsel 35
Aug 09, 2018: INSYS Therapeutics appoints Elizabeth Bohlen to Board of Directors 36
Apr 02, 2018: INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors 37
Feb 01, 2018: INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors 38
Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 39
Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 40
Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 41
May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 42
May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 43
Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 44
Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 45
Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 46
Legal and Regulatory 47
Aug 22, 2018: Justice Department takes first-of-its-kind-legal action to reduce opioid over-prescription 47
May 15, 2018: INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts 51
Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 52
Product News 53
07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 53
05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 54
Product Approvals 55
Dec 06, 2017: FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics 55
Sep 29, 2017: INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA 56
Mar 23, 2017: DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug 57
Clinical Trials 58
Dec 07, 2017: INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis 58
Other Significant Developments 59
Jun 18, 2018: INSYS Therapeutics Provides an Update on Its Ongoing Transformation 59
Feb 09, 2018: INSYS Therapeutics Addresses Maryland Attorney General’s Motion 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
INSYS Therapeutics Expands Agreement with University of California San Diego 12
INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13
Insys Therapeutics Enters into Licensing Agreement with Senzer 14
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16
Insys Therapeutics Completes IPO For US$36.8 Million 17
Insys Therapeutics Inc, Key Competitors 19
Insys Therapeutics Inc, Key Employees 20
Insys Therapeutics Inc, Other Locations 21
Insys Therapeutics Inc, Subsidiaries 21

List of Figures
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Insys Therapeutics Inc (INSY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Marquette Capital Partners LLC:企業の戦略・SWOT・財務分析
    Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report Summary Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cathedral Energy Services Ltd (CET):石油・ガス:M&Aディール及び事業提携情報
    Summary Cathedral Energy Services Ltd (Cathedral) is an oil and gas company that provides drilling and completion services. The company's services include horizontal and directional drilling services, flowback and production testing, measurement while drilling services, production testing services, …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Calithera Biosciences Inc (CALA):企業の財務・戦略的SWOT分析
    Summary Calithera Biosciences Inc (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminas …
  • Westwater Resources, Inc.:企業の戦略・SWOT・財務情報
    Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tampa Electric Co:企業の戦略的SWOT分析
    Tampa Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Hydro-Electric Corporation:企業の戦略的SWOT分析
    Hydro-Electric Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Bosch Rexroth AG:企業の戦略的SWOT分析
    Bosch Rexroth AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Gebr. Heinemann SE & Co KG:企業の戦略・SWOT・財務分析
    Gebr. Heinemann SE & Co KG - Strategy, SWOT and Corporate Finance Report Summary Gebr. Heinemann SE & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CSL Ltd (CSL):医療機器:M&Aディール及び事業提携情報
    Summary CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and second …
  • AIA Bhd:企業の戦略・SWOT・財務情報
    AIA Bhd - Strategy, SWOT and Corporate Finance Report Summary AIA Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Dentsply Sirona Inc (XRAY):医療機器:M&Aディール及び事業提携情報
    Summary Dentsply Sirona Inc (Dentsply Sirona) formerly Dentsply International Inc, is a medical device company that designs, develops, manufactures and markets a wide range of products for the dental market. It provides dental prosthetics, precious metal dental alloys, dental ceramics, endodontic in …
  • Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析
    Summary Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company's pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treatin …
  • Shenzhen Topray Solar Co Ltd (002218):企業の財務・戦略的SWOT分析
    Shenzhen Topray Solar Co Ltd (002218) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Ascom Holding AG:企業のM&A・事業提携・投資動向
    Ascom Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ascom Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Fast Retailing Co., Ltd.:戦略・SWOT・企業財務分析
    Fast Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fast Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Oceania Cruises, Inc.:企業の戦略・SWOT・財務分析
    Oceania Cruises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Oceania Cruises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fujikura Ltd.:企業の戦略・SWOT・財務情報
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • University of Aberdeen:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Aberdeen (UOA) is an educational and research institution that offers educational and research programs. The university offers undergraduate, graduate, postgraduate and research programs. It provides undergraduate and postgraduate courses in the areas of education, creative art …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆